Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Morphosys-Galapagos, Therapeutic Antibodies
Volgen
de tuinman schreef op 13 januari 2020 22:47 :
[...]
9% is wel erg veel.
In duitsland doen ze alles grondig. Die jefferies commentaar las ik ergens op een duitse site trouwens. Maar was nogal summier.
www.biopharmadive.com/news/incyte-mor... Incyte turns to German Morphosys to refresh cancer pipeline
Eventjes wat getalletjes opgesnord over Morphosys in 2019Q3 rapport. Cash Positie : 412 miljoen Euro EBIT nodig per jaar : ongeveer 110 miljoen Euro. Ze konden dus nog een jaartje of vier verder. Maar, nu komt er een betalingske van 750 miljoen euro wegens de deal met Incyte. Moet er niet echt een tekeningtje bij maken wat dat dat zou kunnen betekenen ???
Toert schreef op 14 januari 2020 14:41 :
Eventjes wat getalletjes opgesnord over Morphosys in 2019Q3 rapport.
Cash Positie : 412 miljoen Euro
EBIT nodig per jaar : ongeveer 110 miljoen Euro.
Ze konden dus nog een jaartje of vier verder.
Maar, nu komt er een betalingske van 750 miljoen euro wegens de deal met Incyte.
Moet er niet echt een tekeningtje bij maken wat dat dat zou kunnen betekenen ???
Incyte will also invest $150 million in MorphoSys stock and agreed to extend another $1.1 billion in conditional payments should development of tafasitimab hit certain clinical, regulatory and sales milestones.
Toert schreef op 13 januari 2020 22:44 :
@wall street trader:
Ik las ergens dat jefferies Incyte een slechte keuze vond. Vind je daar iets van terug ?
Ik dacht eerst dat de vrije val daardoor kwam, maar blijkbazr is de beweging voor alle biotech. Komt wel goed.
@Toert I read the report from Jefferies yesterday briefly.... Can't find it anymore I'm sorry. But it didn't provide much information. They weren't too keen on the deal. Hereby some new views on Morphosys:Piper says terms of Incyte deal 'attractive' for Morphosys Piper Sandler analyst Danielle Brill maintained an Overwight rating and $42 price target on MorphoSys (MOR) after the company announced a global collaboration with Incyte (INCY) for the development of tafasitamab. Brill said the deal is "great" in terms of economics and future governance of the assets, though she does believe investors will question whether Incyte is the "ideal" partner to unlock tafasitamab's full potential. The analyst noted, however, that she does believe tafa will be a "top-priority" for both companies, and they will be equally committed to insuring it is a commercial success.Incyte (INCY) and MorphoSys (MOR) analyst commentary from Goldman Sachs MorphoSys collab deal an 'incremental positive' for Incyte, says Goldman Sachs. Goldman Sachs analyst Salveen Richter says the global collaboration and license agreement between Incyte (INCY) and MorphoSys (MOR) to develop and commercialize tafasitamab for B-cell malignancies is an "incremental positive" for Incyte, as it adds a near commercial stage asset. Under the terms of the deal, the companies will co-commercialize tafasitamab with a 50:50 profit split in the U.S., while Incyte will have exclusive commercialization rights excluding the U.S. Outside of the initial indication, Incyte and MorphoSys will also explore monotherapy use of tafasitamab in other B cell malignancies as well as in combination with Incyte's parsaclisib, which Richter says offers upside to his numbers. He made no change to his Conviction Buy rating and $107 price target for Incyte shares.MorphoSys analyst commentary from JMP Securities Incyte price target raised to $121 from $99 at JMP Securities. JMP Securities analyst Reni Benjamin raised his price target on Incyte (INCY) to $121 and kept his Outperform rating after the company announced a global collaboration and license agreement for tafasitamab with MorphoSys (MOR) yesterday. Despite the $900M cash payment upon closing by Incyte, the analyst believes that the deal is net-positive for both companies as Incyte gains a "significant" mid-to-long term revenue driver while MorphoSys gets access to its established "hematology/oncology network and expertise."
Bryan Garnier & Co Morphosys (Buy) PT € 140 Fair Value EUR140 (14th January 2020)Incyte is a great partner, but is it the best? Given the market’s reaction following yesterday’s announcement ($MOR: -9% at EU closing), we acknowledge that investors think Incyte is not the best possible partner (while some had expected a buyout). Although we were also hoping for a bigger name, some kind of price needed to be paid to keep half of the US rights and leverage them to build up MorphoSys’ US commercial franchise. While Incyte is not AstraZeneca, it nevertheless has strong expertise in haematology as well as an extended commercial footprint in the US and in Europe. On top of that, while big pharmas can deprioritise projects on the go, we are expecting Incyte to stay fully committed in view of the investment made. Can it help deliver the USD3.5bn in sales that we forecast at peak? We think so. Especially since Incyte already covers most of the physicians treating DLBCL in the US and Europe. Bottom line, Incyte is the best partner MorphoSys could get without losing all control oover its most important drug and biggest value-driver.Incyte aims to open new horizons, but this comes at a cost Although we also believe that Tafasitamab has a strong potential beyond DLBCL, it is worth bearing in mind that all these new developments will also be supported by MorphoSys at a rate of 45%. While no timing has been disclosed for now, Incyte is planning to start a combination study with its proprietary PI3K-delta inhibitor parsaclisib in R/R B-cell malignancies, a phase III in follicular lymphoma/marginal zone lymphoma as well as potential registration-enabling studies in CLL. Beyond the financing perspective, this raises some questions regarding the recent collaboration initiated with Vivoryon Therapeutics. Signed before Jean-Paul Kress' arrival, it was looking to combine Tafa with PQ912, a CD47-SIRP. Will parsaclisib kill PQ912? Time will tell.Financial terms are attractive, although only partially disclosed We are indeed lacking precision regarding the type of tiered royalty system or the way the USD1.1bn in milestones will be split between the regulatory, development and commercial steps. The only certainty is the USD750m upfront payment that will strengthen the company’s cash position for sure. In all, we believe the deal is rich for MorphoSys and that it should start paying off with the potential FDA approval around mid-2020. After incorporating those new elements into our scenario, we come up with an identical FV of EUR140 as before.An acquisition is off the table now, but was it ever on? In view of yesterday’s stock performance, we acknowledge that investors were expecting a deal with a big pharma that could have opened the door to a later buyout. But in all fairness, with MorphoSys’ management this scenario has never been on the table. With an FDA approval in sight, several milestones on the way, an extended development programme planned, a fully committed partner and a discounted valuation, we are reiterating our Buy rating with a FV of EUR140.
Dank je wel, wall street trader ! Great info !!!
Eli Lilly & Co. (LLY) and Incyte Corp. (INCY) said Monday that baricitinib met the primary endpoint in the Breeze-AD4 investigational phase 3 study. The companies said they evaluated the safety and efficacy of baricitinib in combination with topical corticosteroids for the treatment of adult patients with moderate to severe atopic dermatitis who were inadequate responders, intolerant or had contraindication to treatment with cyclosporine. The primary endpoint was defined by the proportion of patients achieving at least a 75% or greater change from baseline in their Eczema Area and Severity Index at week 16. The study evaluated the efficacy and safety of the 1-mg, 2-mg and 4-mg doses of baricitinib, and the 4-mg dose of baricitinib plus topical corticosteroids met the primary endpoint as defined by the proportion of participants achieving Eczema Area and Severity Index at week 16. The companies said the safety profile was consistent with the known safety findings of baricitinib in atopic dermatitis. The most common treatment-emergent adverse events included nasopharyngitis, headache, and influenza. No venous thromboembolic events or deaths were reported in the trial. Lilly recently submitted baricitinib for regulatory review in Europe as a treatment for patients with moderate to severe atopic dermatitis and plans to submit for approval in the U.S. and Japan in 2020. Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries, including the U.S., member states of the EU and Japan, and is marketed as Olumiant. Write to Chris Wack at chris.wack@wsj.com (END) Dow Jones Newswires January 27, 2020 07:16 ET (12:16 GMT)
Roel76 schreef op 12 februari 2020 11:58 :
twitter.com/datatrials/status/1227333... Kan iemand me daarbij helpen?
Ivm Mor106
www.globenewswire.com/news-release/20...
www.fiercebiotech.com/biotech/lilly-a... Anti-amyloid beta antibodies in development at Eli Lilly and Roche have failed to improve outcomes in a phase 2/3 Alzheimer’s disease trial. Despite the setback, Roche is continuing two phase 3 trials of its asset in a broader population of Alzheimer’s patients.
goed nieuws, misschien eindelijk eens wat definitiever naar hogere niveaus
Toert schreef op 14 januari 2020 22:22 :
Dank je wel, wall street trader !
Great info !!!
Bryan Garnier & Co Morphosys (Buy) PT € 140 (2 March 2020)
Nog wat extra goed nieuws vandaag over Morphosys : March 3 (Reuters) - Morphosys Ag MORG.DE : * DGAP-NEWS: MORPHOSYS AND INCYTE ANNOUNCE ANTITRUST CLEARANCE OF GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR TAFASITAMAB * AGREEMENT BECOMING EFFECTIVE TRIGGERS $750 MILLION UPFRONT PAYMENT BY INCYTE TO MORPHOSYS * MORPHOSYS - AGREEMENT BECOMING EFFECTIVE TRIGGERS INCYTE'S EQUITY INVESTMENT INTO CO OF $150 MILLION IN NEW ADS WITHIN DEFINED TIMELINES
fijn want de koers was wat zwak.
De 2019 resultaten zijn er :www.morphosys.com/media-investors/med... Van MOR106 nergens geen sprake meer, maar dat wisten we al. Hun vooruitzichten zien er goed uit, ongeveer brake even in 2020 (dit jaar nog 100 miljoen verlies), en dat zonder rekening te houden met eventuele inkomsten uit tafasitamab. Zij weten al de datum van de FDA uitspraak of ze mogen verkopen of niet : 30 augustus 2020. Zal een drukke periode worden, ook filgo zou dan (net) goedgekeurd moeten zijn.
de tuinman schreef op 7 mei 2020 18:11 :
Wat gebeurt er bij Mor?
Herstel van veel te veel gezakt ? ZIj bevestigen nog altijd 30 augustus of eerder als goedkeuringsdatum voor hun FDA oordeel.
Oei, best wel stil hier. Maar ik heb ze nog steeds. Rustig laten rijpen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)